All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
#EHA2024: Chronic lymphocytic leukemia and small lymphocytic lymphoma
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up with our live social media relating to chronic lymphocytic leukemia and small lymphocytic lymphoma, here.
CONGRESS #EHA2024 | @NitinJainMD @MDAndersonNews reports results of the phase 2 trial of pirtobrutinib, venetoclax & obinutuzumab in first-line treatment of pts with CLL. N=40, mFU=11.7 mo, 6 mo uMRD was 64% (PB=79%), 12-mo uMRD was 85% (PB=90%). Safety profile was similar to the… pic.twitter.com/b6fyC82jWr
— Lymphoma Hub (@lymphomahub) June 14, 2024
CONGRESS #EHA2024 | Arnon P. Kater @amsterdamumc shared early results of the EPCORE CLL-1 trial of epcortitamab in Richter's transformation (RT). N=35, mFU=8.1 mo, ORR was 53% (60% & 44% in 1L RT & 2L RT, resp), CR rate was 42% (50% & 33% in 1L RT & 2L RT, resp), OS was 11.7 mo,… pic.twitter.com/7KJqjY1zBS
— Lymphoma Hub (@lymphomahub) June 14, 2024
CONGRESS #EHA2024 | Paolo Ghia @MyUniSR reports preliminary results from the Arm D of phase 3 SEQUOIA trial of zanubrutinib + venetoclax in treatment-naive CLL/SLL with del(17P) and/or TP53. N=66, mFU 31.6 mo, ORR=100%, CR+CRi=48%, uMRD was achieved by 59% pts in ≥1 PB sample,… pic.twitter.com/G9YwrrZOuS
— Lymphoma Hub (@lymphomahub) June 14, 2024
CONGRESS #EHA2024 | Kerry Rogers at the Ohio State University reports 7-year update on a phase 2 trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for CLL. N=75, mFU=27.9 mo, uMRD status was achieved in 44%, 52%, 60% of RR, TN1, TN2 pts resp. mPFS was 81.8 mo, 88.5… pic.twitter.com/5a10ahJvnI
— Lymphoma Hub (@lymphomahub) June 14, 2024
CONGRESS #EHA2024 | Poster | Santiago Ossorio Prendes at hospital universitario gregorio marañon, reports 6-year time to next treatment extrapolation curve from the GLOW trial of first-line ibrutinib + venetoclax in elderly/unfit pts with CLL. N=8, projected proportion of… pic.twitter.com/TgG5PRGsv9
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS #EHA2024 | Poster | Jennifer R. Brown @DanaFarber reports patients reported outcomes of ALPINE study of zanubrutinib vs ibrutinib in R/R CLL/SLL. In the PFS model, zanubrutinib shown statistically significant reduction in the risk of investigator-assessed PFS events vs… pic.twitter.com/a84EQllf4m
— Lymphoma Hub (@lymphomahub) June 15, 2024
CONGRESS | #EHA2024
— Lymphoma Hub (@lymphomahub) June 16, 2024
William Wierda @wwierda @MDAndersonNews presents exploratory analyses from TRANSEND CLL 004 trial in heavily pre-treated patients with R/R #CLL/#SLL (median 5 prior lines of therapy).
▪️ Lower baseline disease burden was associated with achievement of… pic.twitter.com/OitNReB1u8
CONGRESS #EHA2024 | Poster | Jan Burger @MDAndersonNews reports phase 2 study of time-limited treatment with acalabrutinib plus obinutuzumab in pts with treatment-naïve CLL. N=28, estimated 2 yr PFS & OS were 95.8%. ORR=100%, CR=67%, PR=33% at end of therapy. BM infiltration by… pic.twitter.com/hBJiEE4ELA
— Lymphoma Hub (@lymphomahub) June 15, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What types of support services or resources do you think would best facilitate the safe implementation of the BrECADD regimen in clinical practice?
